Buscar
Mostrando ítems 1-10 de 1704
Investigación y desarrollo de nuevos medicamentos: de la molécula al fármaco
(Sociedad Médica de Santiago, 2001)
Estudos de medicamentos biosimilares
(2010-09-01)
In Brazil, the registration of new drugs is carried out only when the regulatory agency (Anvisa, acronym in Portuguese) is fully satisfied with the evidence of their quality, efficacy and safety, presented by a pharmaceutical ...
Estudos de medicamentos biosimilares
(2010-09-01)
In Brazil, the registration of new drugs is carried out only when the regulatory agency (Anvisa, acronym in Portuguese) is fully satisfied with the evidence of their quality, efficacy and safety, presented by a pharmaceutical ...
Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America
(Springer, 2019)
The use of biosimilar drugs for multiple sclerosis (MS) has become widespread in Latin America, with the goal of reducing costs of treatments, promoting the sustainability of healthcare systems, and improving patient ...
The preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
(Taylor and Francis Ltd, 2020)